WASHINGTON, April 30, 2019 /PRNewswire/ -- The National Organization for Rare Disorders® (NORD), the leading independent nonprofit organization representing the 25-30 million Americans living with rare diseases, is celebrating the 30th anniversary of its Rare Disease Research Grant Program by announcing the availability of eleven new funding opportunities to support the study of eight rare diseases. The initial application deadline is June 18, 2019.
NORD's Rare Disease Research Grant Program is accepting proposals for scientific and/or clinical research studies of:
Alveolar Capillary Dysplasia with Misalignment of the Pulmonary Veins (ACD/MPV) — One grant of up to $50,000 U.S.
Appendix Cancer and Pseudomyxoma Peritonei (PMP) — Two grants of up to a combined total of $100,000 U.S.
Autoimmune Polyglandular Syndrome Type 1 (APS-1) — One grant of up to $100,000 U.S.
Biliary Atresia — Two grants of up to a combined total of $190,500 U.S.
Malonic Aciduria — One grant of up to $52,000 U.S.
Neuroendocrine Cell Hyperplasia of Infancy (NEHI) — One grant of up to $30,000 U.S.
New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) — Two grants of up to a combined total of $100,000 U.S.
Primary Orthostatic Tremor — One grant of up to $42,500 U.S.
NORD encourages all U.S. and international researchers interested in studying one or more of these diseases to click here to review the complete application guidelines detailed in the request for proposals.
NORD's Rare Disease Research Grant Program provides seed funding to qualified researchers for translational or clinical studies related to the development of potential new diagnostics or treatments for rare disease. Over the past thirty years, NORD grants have led to the development of two FDA-approved treatments and numerous peer-reviewed publications. More than 150 grants have been awarded representing over $8 million in approved funding since the program's launch in 1989.
"For the last 30 years, we have been so inspired by the generous support of our donors," said Vanessa Boulanger, NORD's Director of Research Programs. "The rare disease community has a deep understanding of the critical need to engage with scientists to support novel research that accelerates the development of discoveries that save lives. As we celebrate the 30th anniversary of NORD's Research Grant Program, we also celebrate collaboration and partnership within the community. We hope you will join us for another 30 years of driving rare disease research forward!"
Grants are made possible through the generosity of allies in the rare disease community and supporters who have donated into NORD's research fund. For more information about NORD's Rare Disease Research Grant Program and rare disease research funding opportunities, visit: http://rarediseases.org/research.
About the National Organization for Rare Disorders (NORD)®
The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseases. NORD is committed to the identification, treatment and cure of the more than 7,000 rare diseases, of which approximately 90 percent are still without an FDA-approved treatment or therapy. Rare diseases affect 25-30 million Americans. More than half of those affected are children.
NORD began as a small group of patient advocates that formed a coalition to unify and mobilize support to pass the Orphan Drug Act of 1983. For more than 35 years, NORD has led the way in voicing the needs of the rare disease community, driving supportive policies and education, advancing medical research and providing patient and family services for those who need them most. NORD is made strong together with over 280 disease-specific member organizations and their communities and collaborates with many other organizations on specific causes of importance to the rare disease patient community.
SOURCE National Organization for Rare Disorders (NORD)